Know About Genome Sequencing Labs in India

Offering Affordable Genomics Worldwide

MedGenome has been a pioneer in delivering affordable, global-quality omics testing and research services in India, offering over 1300 genetic tests to diagnose rare and inherited conditions, cancer, and preventive wellness screening. Our deep-rooted commitment to scientific excellence is evident through our contribution to 1000+ citations across 180+ research papers, our talent pool of 1300+ employees, comprising of more than 200 in-house scientific experts and the trust and credibility we have built with our prescriber network across the country. While science guides all our innovations, our technological capabilities including clinically validated proprietary assays, AI/ML enabled bioinformatics platform and in-house developed variant analysis tools enable us to transform them into real world applications. Today, MedGenome provides its services to patients and healthcare providers across 600+ locations in India and in about 40 countries. We are committed to driving early intervention and advancing precision medicine through our innovative in-house developed omics solutions.

Our Values

Science

All proprietary tests are backed by validated research studies and publications in reputed scientific journals.

Innovation

The first Indian company continuing to bring several in-house developed breakthrough genetic tests to the market.

Quality

The largest CAP-accredited genetic testing laboratory in South Asia to have end-to-end multiomics capabilities across all major disease areas.

Technology

Proprietary bioinformatics analysis platform transforming innovations into real world applications to improve healthcare outcomes.

Our Expertise

We are South Asia’s largest CAP-accredited genetic testing laboratory, operating in India with the most extensive menu of over 1,300 advanced genetic tests. Our offerings help detect and diagnose complex disorders in disease areas including rare inherited diseases, reproductive health, oncology, infectious diseases and preventive wellness.

Vision and Mission

Our Vision is to make genomic healthcare affordable, accessible, and equitable to reduce the disease burden in the country. By building awareness around the impact of early intervention on improving patient outcomes, we have been consistently working towards advancing precision medicine.

Our Mission is to enable early and accurate diagnosis and targeted disease management through genomics and molecular level actionable insights. We develop science backed innovative omics solutions that guide clinicians in diagnosis and treatment of complex diseases and bring hope to patients and families around the world.

Raised $47.5mn from Maj Invest, Novo Holdings and Sofina.

2025

Marked 10 years of pioneering genomics in India.
Acquired majority stake in Odisha based Gen X Diagnostics.

2024

Acquired majority stake in Delhi based Prognosis Laboratories.
Acquired South Asia’s first NovaSeq X Plus.
Launched Low Pass WGS KaryoSeq test.

2023

Secured Series D funding of $50m led by Novo Holdings.

2022

Secured Series C3 funding of $16.5M led by IFC World Bank Group.
Acquired majority stake in Bangalore based Trident Diagnostics.
Launched personal genomics division, Genessense.

2021

Secured $55M Series C2 funding led by Leapfrog.
Launched comprehensive TB portfolio.

2020

Launched polygenic risk score-based test for coronary artery disease.

2019

Secured Series C1 funding $40M led by Sequoia India, Sofina, Zodius Capital & HDFC.
Received CAP accreditation for Bangalore lab.
Launched proprietary liquid biopsy for MRD.